linjc16/ctgov huggingface dataset:
French National Observatory of Aortic Syndromes

Study Overview
=================
Brief Summary
-----------------
The study examined the clinical characteristics and conditions of care for patients with acute aortic syndrome (AAS) that will identify patients at risk for increased morbidity and mortality and provide a basis for the eventual achievement of specific studies on the optimal therapeutic management according to different risk profiles. The aim of the Observatory is to provide a photograph size of practices in France at present, both in the larger centers than in smaller and optimize diagnostic and therapeutic currently available by the activation pathways of rational management.

Official Title
-----------------
French National Observatory of Aortic Syndromes

Conditions
-----------------
Acute Aortic Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female age (e) over 18 years old Patients with a AAS duly authenticated by further tests Patients who consented to participate in the study Exclusion Criteria: Refusal of consent for study participation and ancillary studies AAS occurring in the aftermath of a traumatic thoracic Diagnosis AAS aside in favor of an alternative diagnosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Acute Aortic Syndrome<br>Patients admitted to cardiology, radiology or surgery for a clinical picture suggestive of acute aortic syndrome whose diagnosis was subsequently confirmed in due course of hospitalization by further investigations. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Etiology of AAS | Measure the respective contribution of each of the etiologies of AAS (aortic dissection type A aortic dissection type B aortic wall hematoma, penetrating atherosclerotic ulcer, aneurysm of the thoracic aorta complicated). | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical picture | Identify and define the specific clinical picture of each of these new entities recently dismembered as part of AAS. Indeed, if the clinical presentation of classic aortic dissection A and B is well known, that of other entities, individualized recently, remains poorly described. | 1 day | 
| Diagnostic tests | Evaluate the performance and the respective roles of the various diagnostic tests including recent acquisitions little or no invasive; Trans thoracic ultrasound, ultrasound and trans esophageal chest scan. | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute aortic syndrome
The Incidence of Treatment-requiring Retinopathy of Prematurity in Greece

Study Overview
=================
Brief Summary
-----------------
A prospective observational study of the incidence of treatment-requiring ROP (TR-ROP), at a national level, in Greece.

Detailed Description
-----------------
The purpose of this observational study is to prospectively collect data on ROP cases necessitating treatment at a national level. Each and every ROP screening unit in Greece (collaborating centers) report their new TR-ROP cases, their demographics and treatment characteristics, monthly, for a 12-month period. A reminder email is sent to avoid under-reporting due to neglect. Data are collected by the Responsible Party and will be analyzed together with national registry data on all preterm births in the same 12-month period.

Official Title
-----------------
The Incidence of Treatment-requiring Retinopathy of Prematurity in Greece: a Multicenter Prospective Cohort Study

Conditions
-----------------
Retinopathy of Prematurity

Intervention / Treatment
-----------------
* Other: Other: observational study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Preterm infants undergoing screening for ROP, who developed TR-ROP and were treated for ROP in one or two eyes. Exclusion Criteria: None.

Ages Eligible for Study
-----------------
Minimum Age: 30 Weeks
Maximum Age: 50 Weeks

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Infants treated for ROP<br> | Other: Other: observational study<br>* Observational study<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The incidence of treatment-requiring ROP (TR-ROP) in Greece |  | During the study period (1 year, prospectively) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The mean gestational age and birth weight of infants treated for ROP in Greece |  | During the study period (1 year, prospectively) | 
| The rate of participants treated with laser photocoagulation versus anti-VEGF injection |  | During the study period (1 year, prospectively) | 
| The failure and recurrence rate of applied treatments for ROP |  | During the follow-up period (6 months from treatment, prospectively) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Retinopathy of prematurity, ROP, Treatment
Energy Expenditure

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to standardize methods in measuring a person's energy expenditure. These methods may be used in a larger study in the future.

Official Title
-----------------
Energy Expenditure

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adults must be 18 years of age or older children must be between 6 and 88 pounds Exclusion Criteria: pulmonary or respiratory disorders
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Children<br>healthy children | |
| Adult<br>healthy adults | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
healthy adults, healthy children
Right Ventricular Function in Obstructive Sleep Apnea

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the structural and functional cardiac alterations in obstructive sleep apne (OSA) independent from systemic and pulmonary arterial hypertension and their correlation to the severity of OSA.

Detailed Description
-----------------
Many risk factors for OSA, such as male gender, obesity, and increasing age are the same as for cardiovascular diseases. This fact makes it more difficult to establish a causal relationship between OSA and cardiovascular diseases. The relationship between OSA and right ventricular (RV) function is controversial. RV dysfunction may be a result of chronic intermittent hypoxia and hypercapnia during apneic episodes. It may also occur secondary to left ventricular dysfunction as a result of increased afterload and sympathetic activity which causes secondary hypertension. As systemic hypertension is one of the most accompanying and contributing factors in OSA along with obesity, we tried to compare the effects of newly diagnosed OSA on RV function with an age and body mass index- matched control group.

Official Title
-----------------
The Evaluation of Subclinical Right Ventricular Dysfunction in Obstructive Sleep Apnea Patients Without Systemic and Pulmonary Arterial Hypertension Using Velocity Vector Imaging

Conditions
-----------------
Sleep Apnea, Obstructive

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: For OSA patients (group1) Apnea Hypopnea Index equal or more than 15 Epworth sleepiness scale equal or more than 10 No previous treatment for OSA Exclusion Criteria: Age < 18 years Known hypertension, or 24-hour mean blood pressure of 135 and/or 85 mmHg or more Mean pulmonary artery pressure > 25 mmHg Diabetes mellitus Left ventricular ejection fraction < 60% Moderate to severe valvular disease Cardiomyopathy Renal failure Coronary artery disease Obstructive or restrictive lung disease demonstrated on pulmonary function test Connective-tissue or chronic thromboembolic disease Pericardial disease Cancer and/or other important comorbidities with an expected survival < 2 years Suboptimal echocardiographic images for measurements

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Newly diagnosed obstructive sleep apnea patients without systemic and pulmonary arterial hypertension | |
| 2<br>Age, sex and and body mass index-matched matched healthy subjects | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Vasosol Organ Perfusion Solution and Medtronic Portable Bypass System

Study Overview
=================
Brief Summary
-----------------
This is a pilot trial of centrifugal machine preservation of donor livers for transplantation using a novel preservation solution.

Official Title
-----------------
Phase 1 Study of Liver Machine Preservation With Vasosol Solution

Conditions
-----------------
Liver Transplantation, Organ Preservation

Intervention / Treatment
-----------------
* Device: Vasosol Organ Perfusion Solution and Medtronic Portable Bypass System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primary/ Solitary Liver Transplant Lab MELD<35 Donor age <65 Exclusion Criteria: Donor Liver > 30% Macrosteatosis DCD donor liver Multi-organ Recipient Recipient in ICU Retransplant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Vasosol Organ Perfusion Solution and Medtronic Portable Bypass System|Utilization of Vasosol with Medtronic System for Machine Preservation of the Liver for Liver Transplantation|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Liver Transplantation, Organ Preservation, Liver Preservation, Machine Perfusion, Vasosol, Machine Preservation
Gastroesophageal Reflux During LMA in Control Ventilation (LMA, Laryngeal Mask Airway)

Study Overview
=================
Brief Summary
-----------------
Laryngeal mask airway is seldom used for control ventilation in America, while it is popular in China. The question is whether the incidence of gastroesophageal reflux in control ventilation is really higher than in spontaneous ventilation. So the investigators combine the third generation laryngeal mask and catheter-based Digitrapper ph-Z monitor system to evaluate the exact incidence of gastroesophageal reflux in these two groups.

Detailed Description
-----------------
Patients scheduled for LMA ventilation are divided into two groups randomly, control ventilation group and spontaneous ventilation group. After the third generation laryngeal mask is inserted, catheter-based Digitrapper ph-Z monitor system is applied to measure the exact incidence of gastroesophageal reflux in these two groups.

Official Title
-----------------
Incidence of Gastroesophageal Reflux During LMA Application in Control and Spontaneous Ventilation

Conditions
-----------------
Gastroesophageal Reflux

Intervention / Treatment
-----------------
* Procedure: control ventilation
* Procedure: spontaneous ventilation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients for lower extremity operations; patients for urological operations; patients for gynecological operations. Exclusion Criteria: gastroesophageal reflux disease; body mass index more than 30.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: control ventilation<br>patients are scheduled to receive control or spontaneous ventilation | Procedure: control ventilation<br>* patients are randomly divided to receive control or spontaneous ventilation randomly.<br>Procedure: spontaneous ventilation<br>* patients are randomly divided to receive control or spontaneous ventilation randomly.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of gastroesophageal reflux of participants | evaluate the exact incidence of reflux in LMA patients with catheter-based Digitrapper ph-Z monitor system | participants will be monitored for the duration of laryngeal mask application, an expected average of 1.5 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Gastroesophageal Reflux, Laryngeal Mask Airway, Control Ventilation, Spontaneous Ventilation
The Clinical and Biochemical Characteristics in Women With Different Menstrual Pattern

Study Overview
=================
Brief Summary
-----------------
Background: Menstrual disturbance is the major complain in reproductive age women, the clinical and biochemical characteristics of women with different menstrual disturbance had not been well-understood. Objective: To study the clinical and biochemical characteristics of women with oligomenorrhea, amenorrhea, and premature ovarian failure. Method: Retrospective study, medical records reviewed in patients who visited to outpatient clinic of Reproductive Medicine in Taipei Medical University - Wan Fang Hospital form 2009 Jan. 1 to 2011 Nov. 31. Including criteria: Patients had sufficient medical records (anthropometric, endocrine, metabolic, lipid parameters) and age less than 45. Excluding criteria: (1) Women who experienced menarche <3 years before the beginning of the study; (2) Women who received hormones or drugs for major medical diseases; (3) Women who presented ovarian cysts or ovarian tumors, uterine abnormality; (4) Women who were >45 years old.

Conditions
-----------------
Regular Menstrual Cycle, Irregular Menstrual Cycle

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients had sufficient medical records (anthropometric, endocrine, metabolic, lipid parameters) and age less than 45. Exclusion Criteria: Women who experienced menarche <3 years before the beginning of the study; Women who received hormones or drugs for major medical diseases; Women who presented ovarian cysts or ovarian tumors, uterine abnormality; Women who were >45 years old.

Ages Eligible for Study
-----------------
Minimum Age: 13 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control<br> | |
| Oligomenorrhea<br> | |
| Amenorrhea<br> | |
| premature ovarian failure<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients

Study Overview
=================
Brief Summary
-----------------
The investigators are interested in identifying patient-specific factors related to donor chimerism in patients who receive nonmyeloablative hematopoietic stem cell transplants from haploidentical donors. We will look how patients' bodies break down and immediately respond to cyclophosphamide, fludarabine and mycophenolate mofetil.

Official Title
-----------------
Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients

Conditions
-----------------
Leukemia, Hodgkin Disease, Non-Hodgkin Lymphoma, Myelodysplastic Syndrome, Multiple Myeloma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Scheduled to receive nonmyeloablative conditioning which includes fludarabine Scheduled to receive a haploidentical graft Scheduled to receive postgrafting immunosuppression which includes oral mycophenolate mofetil (MMF) or enteric-coated mycophenolic acid Age >18 years at the time of enrollment Exclusion Criteria: Diagnosed with an immunodeficiency disorder, including HIV

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Donor T-cell chimerism |  | Day 28 post-transplant | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Exposure to cyclophosphamide, fludarabine, and mycophenolate mofetil and their breakdown products |  | 1 week before through 3 weeks after transplant | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hematopoietic stem cell transplantation, cyclophosphamide, fludarabine, mycophenolate mofetil, mycophenolic acid, biomarkers
Diagnosis of Oral Precancers and Cancers Using Optic Coherence Tomography

Study Overview
=================
Brief Summary
-----------------
Diagnosis of oral precancers and cancers using optic coherence tomography

Detailed Description
-----------------
Diagnosis of oral precancers and cancers using optic coherence tomography

Official Title
-----------------
Diagnosis of Oral Precancers and Cancers Using Optic Coherence Tomography

Conditions
-----------------
Oral Cancers

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: oral cancer, oral precancers Exclusion Criteria: other diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Optic coherence tomography, oral cancer, oral precancers
Evaluation of the Resection of Adenoma and Colic Adenocarcinoma by EMR Piecemeal or EMR/ESD Hybrid Technique

Study Overview
=================
Brief Summary
-----------------
For tough colic resection, evaluation of our practice for these lesions unresectable in monoblock and evaluation of the contribution of the hybrid technique EMR (mucosectomy dissection) /ESD (submucosal dissection)

Official Title
-----------------
Evaluation of the Resection of Adenoma and Colic Adenocarcinoma by EMR Piecemeal or EMR/ESD Hybrid Technique

Conditions
-----------------
Colorectal Adenoma, Intramucinous Adenocarcinoma

Intervention / Treatment
-----------------
* Procedure: Endoscopic resection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years, Patient with colorectal adenoma or intramucinous adenocarcinoma Exclusion Criteria: Contraindication surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Endoscopic resection|Endoscopic resection with technique EMR piecemeal or hybrid technique EMR/ESD|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relapse rate | Medical follow-up | From surgery to 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complications rate | haemorrhage or perforation | From surgery to 6 months |